MY149620A - Amino quinazolines derivatives with blood platelet reducing properties - Google Patents

Amino quinazolines derivatives with blood platelet reducing properties

Info

Publication number
MY149620A
MY149620A MYPI20092152A MYPI20092152A MY149620A MY 149620 A MY149620 A MY 149620A MY PI20092152 A MYPI20092152 A MY PI20092152A MY PI20092152 A MYPI20092152 A MY PI20092152A MY 149620 A MY149620 A MY 149620A
Authority
MY
Malaysia
Prior art keywords
blood platelet
reducing properties
platelet reducing
derivatives
prodrugs
Prior art date
Application number
MYPI20092152A
Inventor
Franklin Richard
Golding Bernard
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Publication of MY149620A publication Critical patent/MY149620A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THIS INVENTION RELATES TO THE DISCOVERY OF PRODRUGS OF 3-OR 5-SUBSTITUTED ANALOGUES OF THE SELECTIVE PLATELET LOWERING AGENT ANAGRELIDE WHICH HAVE REDUCED POTENTIAL FOR CARDIOVASCULAR SIDE-EFFECTS AND WHICH SHOULD THEREFORE LEAD TO IMPROVED PATIENT COMPLIANCE AND SAFETY IN THE TREATMENT OF MYELOPROLIFERATIVE DISEASES. MORE SPECIFICALLY, THE PRESENT INVENTION RELATES TO PRODRUGS OF CERTAIN IMIDAZOQUINAZOLINE DERIVATIVES WHICH HAVE UTILITY AS PLATELET LOWERING AGENTS IN HUMANS. THE COMPOUNDS OF THE PRESENT INVENTION FUNCTION BY INHIBITING THE FORMATION OF BLOOD PLATELET.
MYPI20092152A 2006-11-28 2007-11-19 Amino quinazolines derivatives with blood platelet reducing properties MY149620A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0623749.9A GB0623749D0 (en) 2006-11-28 2006-11-28 Substituted quinazolines

Publications (1)

Publication Number Publication Date
MY149620A true MY149620A (en) 2013-09-13

Family

ID=37671459

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20092152A MY149620A (en) 2006-11-28 2007-11-19 Amino quinazolines derivatives with blood platelet reducing properties

Country Status (15)

Country Link
EP (1) EP2097390A1 (en)
JP (1) JP2010511031A (en)
KR (1) KR20090089865A (en)
CN (1) CN101558048B (en)
AR (1) AR064003A1 (en)
AU (1) AU2007327048B2 (en)
BR (1) BRPI0719568A2 (en)
CA (1) CA2670168A1 (en)
EA (1) EA017139B1 (en)
GB (1) GB0623749D0 (en)
IL (1) IL198808A0 (en)
MX (1) MX2009005578A (en)
MY (1) MY149620A (en)
TW (1) TW200829252A (en)
WO (1) WO2008065445A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822970D0 (en) * 2008-12-17 2009-01-21 Shire Llc Process for the preparation of anagrelide and analogues
GB201004495D0 (en) 2010-03-18 2010-05-05 Shire Llc Subtituted quinazolines
CN103254197A (en) * 2013-05-29 2013-08-21 黑龙江大学 Preparation method of anagrelide hydrochloride
CN112675178A (en) * 2014-12-22 2021-04-20 速达制药有限公司 Prevention and treatment of metastatic disease in cancer patients with thrombocythemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
DE10301105B4 (en) * 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Use of 2-amino-2H-quinazoline derivatives for the treatment of myeloproliferative disorders, hypertension and bronchodilation
US20040209907A1 (en) * 2003-01-23 2004-10-21 Richard Franklin Formulation and methods for the treatment of thrombocythemia
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia

Also Published As

Publication number Publication date
WO2008065445A1 (en) 2008-06-05
GB0623749D0 (en) 2007-01-10
AU2007327048B2 (en) 2012-01-12
EA017139B1 (en) 2012-10-30
EA200900742A1 (en) 2010-08-30
JP2010511031A (en) 2010-04-08
AR064003A1 (en) 2009-03-04
IL198808A0 (en) 2010-02-17
TW200829252A (en) 2008-07-16
EP2097390A1 (en) 2009-09-09
MX2009005578A (en) 2009-07-29
BRPI0719568A2 (en) 2013-12-10
CN101558048A (en) 2009-10-14
KR20090089865A (en) 2009-08-24
CA2670168A1 (en) 2008-06-05
AU2007327048A1 (en) 2008-06-05
CN101558048B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
NL300701I1 (en)
EA201300556A1 (en) AMINOSPIR-SUBSTITUTED DERIVATIVES 2,3-DIHYDROIMIDAZO [1,2-С] HINAZOLINE, SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISTURBANCES AND DISEASES ASSOCIATED WITH ANGIOGENESIS
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008033562A3 (en) Kinase inhibitor compounds
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
TW200744586A (en) Therapeutic compounds
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
MX2009003724A (en) 2-aminocarbonyl-pyridine derivatives.
MX2010007584A (en) Protein kinase inhibitors and use thereof.
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
WO2006116733A3 (en) Protein kinase inhibitors
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2009005579A (en) Substituted quinazolines.
WO2009138796A3 (en) Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
MY149620A (en) Amino quinazolines derivatives with blood platelet reducing properties
MX2008011020A (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor.
MY148254A (en) Tartrate derivatives for use as coagulation factor ixa inhibitors
EP2124554A4 (en) Compositions and methods for the treatment of cancer
MX2009005912A (en) Heterocyclyl-substituted-ehylamino-phenyl derivatives, their preparation and use as medicaments.
WO2006089664A3 (en) Heterocyclylamide-substituted imidazoles
MX2008013477A (en) Bicyclic tetrahydropyrrole compounds.